Prediction of response to trasutuzumab/pertuzumab/taxane therapy by microRNA in HER2 positive advanced breast cancer

被引：0
|
作者：
Kawachi, A. [1 ]
Shimomura, A. [1 ]
Matsuzaki, J. [2 ]
Kawauchi, J. [2 ]
Takizawa, S. [2 ]
Sakamoto, H. [3 ]
Shimizu, C. [1 ]
Tamura, K. [1 ]
Ochiya, T. [2 ]
机构：
[1] Natl Canc Ctr, Tokyo, Japan
[2] Natl Canc Ctr, Res Inst, Div Mol & Cellular Med, Tokyo, Japan
[3] Natl Canc Ctr, Res Inst, FIOC, Tokyo, Japan
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
123P
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Effectiveness of the trastuzumab-pertuzumab dual block in neoadjuvance of HER2 positive breast cancer
    Ruiz Pena, Ana Cristina
    Dominguez Eguizabal, Beatriz
    Mann Alfaro, Susana
    Fernandez Garcia, Cristina
    Laguna Olmos, Mariano
    Puente Martinez, Maria Jose
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2021, 42 (04) : 721 - 729
  • [32] Efficacy and safety of pertuzumab for HER2 positive metastatic breast cancer: a single institution experience
    Hara, Fumikata
    Aogi, Kenjiro
    Takashima, Seiki
    ANNALS OF ONCOLOGY, 2015, 26 : 141 - 141
  • [33] The association of higher tumor HER2 load with treatment response to neoadjuvant therapy in HER2 positive breast cancer patients
    Lillemoe, T. J.
    Susnik, B.
    Grimm, E.
    Kang, S-H L.
    Swenson, K. K.
    Krueger, J. L.
    Finkelstein, M. J.
    Tsai, M. L.
    CANCER RESEARCH, 2017, 77
  • [34] Prediction of Trastuzumab treatment response for HER2-positive breast cancer by microRNA profiling
    Sato, F.
    Wang, Z.
    Ueno, T.
    Myomoto, A.
    Takizawa, S.
    Masuda, N.
    Mikami, Y.
    Shimizu, K.
    Tsujimoto, G.
    Toi, M.
    CANCER RESEARCH, 2012, 72
  • [35] IS THERE AN OPTIMAL TREATMENT SEQUENCE FOR HER2 POSITIVE ADVANCED BREAST CANCER?
    Arora, Shagun
    Swain, Sandra M.
    BREAST, 2015, 24 : S21 - S22
  • [36] Pathologic response to neoadjuvant therapy in HER2 positive/oestrogen receptor positive breast cancer patients
    Gasol Cudos, A.
    Morales, S.
    Rodriguez Galindo, A.
    Velasco Sanchez, A.
    Serrate Lopez, A.
    Mele Olive, J.
    Canosa Morales, C.
    ANNALS OF ONCOLOGY, 2020, 31 : S333 - S333
  • [37] The perspective of anti-HER2 therapy for HER2 positive breast cancer
    Iwata, Hiroji
    ANNALS OF ONCOLOGY, 2015, 26 : 11 - 11
  • [38] Taxane resistance in breast cancer: A closed HER2 circuit?
    de Hoon, Joep P. J.
    Veeck, Jurgen
    Vriens, Birgit E. P. J.
    Calon, Tim G. A.
    van Engeland, Manon
    Tjan-Heijnen, Vivianne C. G.
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2012, 1825 (02): : 197 - 206
  • [39] Trastuzumab treatment response prediction by microRNAs profile in HER2 positive breast cancer tumors
    Beristain, E.
    Calvo, B.
    Ancizar, N.
    Lahuerta, A.
    Larburu, L.
    Ruiz, I.
    Rezola, R.
    Viguri, M. A.
    Guerra, I.
    Martinez de Pancorbo, M.
    Bediaga, N. G.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2018, 26 : 751 - 752
  • [40] Pertuzumab: A New Targeted Therapy for HER2-Positive Metastatic Breast Cancer
    Malenfant, Stephanie J.
    Eckmann, Karen R.
    Barnett, Chad M.
    PHARMACOTHERAPY, 2014, 34 (01): : 60 - 71
12345